chiniofon has been researched along with Lymphoma--Non-Hodgkin* in 2 studies
2 other study(ies) available for chiniofon and Lymphoma--Non-Hodgkin
Article | Year |
---|---|
114Inm oxine-labelled lymphocytes--therapeutic applications.
It has shown that, after intravenous administration of autologous lymphocytes labelled with the beta-emitting radionuclide 114Inm, the cells initially migrate normally before succumbing to the toxic effects of the radiation. The radioactive material is then released from the cell and taken up by neighbouring radioresistant macrophages, thereby localizing a field of radiation to the site of lymphocyte death. Using this technique, lymphocytopoenia has been produced in rats. We have measured the whole-body distribution and excretion of radioactivity in patients who received escalating activities of 114Inm-labelled lymphocytes. All patients had active non-Hodgkin's lymphoma involving the spleen and liver which proved resistant to combination chemotherapy and conventional radiotherapy. Following intravenous administration, the labelled cells cleared rapidly from the vasculature with only 15% remaining in the peripheral blood at 30 min. The radioactivity continued to fall over the next 5 days to approximately 3% and was maintained at approximately 2% for up to 90 days. There was an almost immediate uptake of radioactivity by the spleen and liver which reached approximately 85% of the injected dose by 48 h. The localization of radioactivity stabilized by 48 h and thereafter the whole-body content fell by approximately 0.8% per day. Up to 5% of the administered radioactivity accumulated in the bone marrow. The activities administered were too low to produce a therapeutic response and no toxicity was experienced by the patients. A therapeutic study at higher activities is now underway. Topics: Humans; Hydroxyquinolines; Indium Radioisotopes; Lymphocytes; Lymphoma, Non-Hodgkin; Organometallic Compounds; Oxyquinoline | 1988 |
Dynamic studies of lymphocytes labelled with indium-111 during and after treatment with monoclonal anti-idiotype antibody in advanced B cell lymphoma.
The migration pattern of lymphocytes labelled with indium-111 was followed in a patient with B cell non-Hodgkin's lymphoma treated with a murine monoclonal anti-idiotype antibody. During the early phase of continuous infusion of antibody rapid fluxes of labelled lymphocytes into and out of the blood were seen. Dynamic scanning showed immediate uptake in the lungs; thereafter activity decreased in the lungs and increased in the liver. Studies of labelled and unlabelled cells in the circulation showed that treatment resulted in the removal of lymphocytes from the blood which was repopulated from an extravascular compartment. Tumour cells were shown to be cleared from the blood by the reticuloendothelial system in the liver. Indium-111 should be used circumspectly because it may cause chromosomal damage in labelled cells, but it is clearly useful as a radiolabel for following the migration pathways of lymphocytes in vivo. Topics: Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Movement; Female; Humans; Hydroxyquinolines; Immunoglobulin Idiotypes; Indium; Leukocyte Count; Lymphocytes; Lymphoma, Non-Hodgkin; Organometallic Compounds; Oxyquinoline; Radioisotopes; Radionuclide Imaging; Time Factors | 1984 |